Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation

被引:2
|
作者
Abay, Merve [1 ]
Ozgen, Levent [1 ]
Yalcin, Yakup [1 ]
Ozerkan, Kemal [1 ]
机构
[1] Uludag Univ, Fac Med, Gynecol Oncol Surg, TR-16059 Bursa, Turkiye
关键词
BRCA; 1/2; Ovarian carcinoma; Serous tubal intraepithelial carcinoma; Risk reducing salpingo-oophorectomy; FOLLOW-UP; CANCER; CARRIERS; OVARIAN; OUTCOMES; SURGERY;
D O I
10.1016/j.jogoh.2023.102642
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Serous tubal intraepithelial carcinoma (STIC) is a precursor lesion which is located in the distal fallopian tube and causes high grade serous ovarian carcinoma (HGSOC). The incidence of STIC for women underwent risk reducing salpingo-oophorectomy for BRCA mutation varies from 0.6 to 7% and its clinical outcomes are still unclear. The aim of this study was to demonstrate the incidence of STIC and HGSOC in BRCA1/2 mutation carriers after risk reducing salpingo-oophorectomy (RRSO) and the clinical outcomes of these patients. Material and methods: We retrospectively reviewed the records of 48 BRCA1 and/or 2 mutation carriers who underwent prophylactic salpingo-oophorectomy with or without hysterectomy at the Department of Obstetrics and Gynecology, Bursa Uludag University between January 2000 and January 2022. Inclusion criteria: BRCA 1 and/or 2 mutation carriers diagnosed by genetic testing, asymptomatic patients with no abnormal findings on pelvic examination. Exclusion criteria: patients with no abnormal findings on pelvic examination and a presence of a personal history of ovarian, fallopian tube or peritoneal cancer. Results: A total of 48 BRCA 1 and/or 2 mutation carriers underwent RRSO. STIC was diagnosed in 1 (2,0%) patient and restaging surgery was not performed. Primary peritoneal carcinoma (PPC) did not develop during the 20 months follow-up period. One (2.0%) patient was diagnosed with occult ovarian cancer. Restaging surgery was performed and chemotherapy treatments were given after surgery. A pelvic recurrence developed 25 months after the occult cancer diagnosis in the follow up period. One (2.0%) patient with normal histopathological findings after RRSO was diagnosed with peritoneal cancer 57 months after the operation. Conclusion: The risk of PPC continues after RRSO. Therefore, close follow-up procedure is very important for early diagnosis and effective treatment of patients with PPC after RRSO.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Occult ovarian cancers at the time of risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers
    Rebbeck, T. R.
    Friebel, T. M.
    Domchek, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy
    Garcia, Christine
    Lyon, Liisa
    Conell, Carol
    Littell, Ramey D.
    Powell, C. Bethan
    GYNECOLOGIC ONCOLOGY, 2015, 138 (03) : 723 - 726
  • [23] Risk-reducing salpingo-oophorectomy and prophylactic mastectomy among BRCA mutation "previvors"
    Holman, Laura L.
    Daniels, Molly S.
    Brandt, Amanda C.
    Arun, Banu
    Keeler, Elizabeth
    Gershenson, David Marc
    Sun, Charlotte C.
    Lu, Karen H.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Characteristics associated with BRCA mutation carriers not undergoing risk-reducing salpingo-oophorectomy
    Oestreich, M. C.
    Wilhite, A.
    Olson, M.
    Erickson, B. K.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 207 - 208
  • [25] Risk-reducing salpingo-oophorectomy and prophylactic mastectomy among BRCA mutation "previvors"
    Holman, L.
    Brandt, A.
    Daniels, M.
    Arun, B.
    Keeler, E.
    Gershenson, D.
    Sun, C.
    Lu, K.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : S17 - S17
  • [26] Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
    Rebbeck, Timothy R.
    Kauff, Noah D.
    Domchek, Susan M.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (02): : 80 - 87
  • [27] Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy
    J. V. Cohen
    L. Chiel
    L. Boghossian
    M. Jones
    J. E. Stopfer
    J. Powers
    T. R. Rebbeck
    K. L. Nathanson
    S. M. Domchek
    Familial Cancer, 2012, 11 : 69 - 75
  • [28] Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy
    Cohen, J. V.
    Chiel, L.
    Boghossian, L.
    Jones, M.
    Stopfer, J. E.
    Powers, J.
    Rebbeck, T. R.
    Nathanson, K. L.
    Domchek, S. M.
    FAMILIAL CANCER, 2012, 11 (01) : 69 - 75
  • [29] Quality of life in BRCA1 and BRCA2 mutation carriers (B1/2) following risk-reducing salpingo-oophorectomy (RRSO).
    Domchek, Susan M.
    Li, Jiaqi
    Digiovanni, Laura
    Voong, Chan
    Mueller, Rebecca
    Johnson, Lauren
    Epperson, C. Neill
    Friedman, Sue
    Gracia, Clarisa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] HISTOPATHOLOGICAL RESULTS AFTER RISK-REDUCING BILATERAL SALPINGO-OOPHORECTOMY IN BRCA1/2 MUTATION CARRIERS: SINGLE CENTER EXPERIENCE
    Ehmann, Sarah
    Ramspott, Jan Philipp
    du Bois, Andreas
    Harter, Philipp
    Schneider, Stephanie
    Baert, Thais
    Traut, Alexander
    Heikaus, Sebastian
    Pauly, Nina
    Ataseven, Beyhan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A81 - A82